This episode deals with the development of extra-musculoskeletal manifestations (EMMs) in patients with psoriatic arthritis or axial spondyloarthritis treated with a Janus-kinase-1-Inhibitor upadacitinib. The study analyzed data from five clinical trials, comparing upadacitinib to placebo and adalimumab. Results indicate low rates of EMM development overall, with numerically lower uveitis rates observed in upadacitinib-treated patients compared to those receiving placebo, particularly in radiographic axial spondyloarthritis.

This episode is based on the publication Poddubnyy D, et al. Arthritis Rheumatol 2024, doi: 10.1002/art.43069.

and developed with Notebook LM.